<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02553460</url>
  </required_header>
  <id_info>
    <org_study_id>TINI</org_study_id>
    <secondary_id>NCI-2015-01493</secondary_id>
    <nct_id>NCT02553460</nct_id>
  </id_info>
  <brief_title>Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I</brief_title>
  <official_title>Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gateway for Cancer Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Texas Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Jude Children's Research Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the good and bad effects of the study drugs bortezomib
      and vorinostat when they are given in combination with chemotherapy commonly used to treat
      acute lymphoblastic leukemia (ALL) in infants. For example, adding these drugs could decrease
      the number of leukemia cells, but it could also cause additional side effects. Bortezomib and
      vorinostat have been approved by the US Food and Drug Administration (FDA) to treat other
      cancers in adults, but they have not been approved for treating children with leukemia. With
      this research, we plan to meet the following goals:

      PRIMARY OBJECTIVE:

        -  Determine the tolerability of incorporating bortezomib and vorinostat into an ALL
           chemotherapy backbone for newly diagnosed infants with ALL.

      SECONDARY OBJECTIVES:

        -  Estimate the event-free survival and overall survival of infants with ALL who are
           treated with bortezomib and vorinostat in combination with an ALL chemotherapy backbone.

        -  Measure minimal residual disease (MRD) positivity using both flow cytometry and PCR.

        -  Compare end of induction, end of consolidation, and end of reinduction MRD levels to
           Interfant99 (ClinicalTrials.gov registration ID number NCT00015873) participant
           outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment will consist of 4 main phases: Remission Induction, Consolidation, Reinduction, and
      Maintenance. High risk patients will receive a reintensification phase prior to transplant in
      first remission.

      REMISSION INDUCTION: Chemotherapy will be given in an attempt to induce the participant's
      leukemia into remission. Drugs given are intrathecal triple drug treatment with methotrexate,
      hydrocortisone and Ara-C (ITMHA); dexamethasone; vorinostat; bortezomib; PEG-asparaginase;
      mitoxantrone; cyclophosphamide; cytarabine; and 6-mercaptopurine.

      CONSOLIDATION PHASE: After the participant's blood counts have recovered from Remission
      Induction, he/she will move to the consolidation phase. This therapy is given to kill any
      remaining leukemia cells. Drugs given are ITMHA, high-dose methotrexate, and
      6-mercaptopurine.

      RE-INDUCTION: This phase aims to improve the participant's overall response to therapy by
      again seeking to bring his/her leukemia into remission. Drugs given are ITMHA, mitoxantrone,
      peg-asparaginase, dexamethasone, bortezomib, and vorinostat.

      RE-INTENSIFICATION: If the participant's maximum residual disease (MRD) is not negative after
      consolidation, he/she will receive intensification therapy, then go on to stem cell
      transplant (SCT) (SCT not part of this study).

      MAINTENANCE PHASE: Participants with negative MRD after consolidation will skip the
      re-intensification phase and proceed to receive maintenance therapy to keep the leukemia from
      returning. Drugs given are ITMHA, dexamethasone, vincristine, 6-mercaptopurine and
      methotrexate. Each cycle of these drugs lasts 28 days and will be repeated up to 20 times as
      long as there are no serious side effects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 29, 2016</start_date>
  <completion_date type="Anticipated">October 2031</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Probability of treatment-related mortality (TRM) during induction or reinduction therapy</measure>
    <time_frame>At the end of reinduction (up to 5 months after start of therapy)</time_frame>
    <description>Tolerability will be measured by the probability of toxic death (Treatment-Related Mortality, TRM) during Induction or Reinduction. As a safety precaution, the study team will suspend enrollment to the study intermittently to prevent more than 10 patients being treated simultaneously with induction and/or re-induction therapy. The study team will consider a &lt; 10% TRM rate as clinically tolerable and will be used as a benchmark.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3-year event free survival (EFS)</measure>
    <time_frame>3 years after completion of therapy (up to 5 years after start of therapy)</time_frame>
    <description>Event-free survival (EFS) will be estimated by the Kaplan-Meier estimator. For EFS, relapse and second malignancies will be considered as failures in addition to death in complete remission. The time to EFS will be set to 0 for patients who fail to achieve complete remission. EFS probability will be estimated with 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-year event free survival (EFS)</measure>
    <time_frame>5 years after completion of therapy (up to 7 years after start of therapy)</time_frame>
    <description>Event-free survival (EFS) will be estimated by the Kaplan-Meier estimator. For EFS, relapse and second malignancies will be considered as failures in addition to death in complete remission. The time to EFS will be set to 0 for patients who fail to achieve complete remission. EFS probability will be estimated with 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>10-year event free survival (EFS)</measure>
    <time_frame>10 years after completion of therapy (up to 12 years after start of therapy)</time_frame>
    <description>Event-free survival (EFS) will be estimated by the Kaplan-Meier estimator. For EFS, relapse and second malignancies will be considered as failures in addition to death in complete remission. The time to EFS will be set to 0 for patients who fail to achieve complete remission. EFS probability will be estimated with 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year overall survival (OS)</measure>
    <time_frame>3 years after completion of therapy (up to 5 years after start of therapy)</time_frame>
    <description>Overall survival (OS) will be estimated by the Kaplan-Meier estimator. OS probability at years 3, 5, 10 will be estimated with 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-year overall survival (OS)</measure>
    <time_frame>5 years after completion of therapy (up to 7 years after start of therapy)</time_frame>
    <description>Overall survival (OS) will be estimated by the Kaplan-Meier estimator. OS probability at years 3, 5, 10 will be estimated with 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>10-year overall survival (OS)</measure>
    <time_frame>10 years after completion of therapy (up to 12 years after start of therapy)</time_frame>
    <description>Overall survival (OS) will be estimated by the Kaplan-Meier estimator. OS probability at years 3, 5, 10 will be estimated with 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare minimal residual disease (MRD) positivity using flow cytometry</measure>
    <time_frame>At end of induction (approximately 6 weeks), end of consolidation (approximately 14 weeks), end of reinduction (approximately 19 weeks), end of reintensification (approximately 23 weeks), and end of maintenance therapy (approximately 2 years)</time_frame>
    <description>Proportion of participants with positive MRD at the end of each therapy block.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare minimal residual disease (MRD) positivity using PCR</measure>
    <time_frame>At end of induction (approximately 6 weeks), end of consolidation (approximately 14 weeks), end of reinduction (approximately 19 weeks), end of reintensification (approximately 23 weeks), and end of maintenance therapy (approximately 2 years)</time_frame>
    <description>Proportion of participants with positive MRD at the end of each therapy block.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean MRD levels compared to the Interfant99 study (NCT00015873)</measure>
    <time_frame>At end of induction (approximately 6 weeks), end of consolidation (approximately 11 weeks), and end of reinduction (approximately 19 weeks)</time_frame>
    <description>The two-sample two-sided Z test at the 5% significance level will be utilized for this comparison.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median MRD levels compared to the Interfant99 study (NCT00015873)</measure>
    <time_frame>At end of induction (approximately 6 weeks), end of consolidation (approximately 11 weeks), and end of reinduction (approximately 19 weeks)</time_frame>
    <description>The two-sample two-sided Z test at the 5% significance level will be utilized for this comparison.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who meet eligibility requirements will receive remission induction, consolidation treatment, reinduction, reintensification and maintenance therapy.
Interventions: ITMHA, dexamethasone, mitoxantrone, pegaspargase or asparaginase Erwinia chrysanthemi, bortezomib, vorinostat, cyclophosphamide, mercaptopurine, methotrexate, leucovorin calcium, cytarabine, etoposide, and vincristine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ITMHA</intervention_name>
    <description>Given intrathecally (IT).</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Intrathecal Triples</other_name>
    <other_name>Methotrexate/hydrocortisone/cytarabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Given orally (PO) or naso-gastrically (NG) or intravenously (IV).</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Decadron®</other_name>
    <other_name>Hexadrol®</other_name>
    <other_name>Dexone®</other_name>
    <other_name>Dexameth®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone</intervention_name>
    <description>Given IV.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Novantrone®</other_name>
    <other_name>Mitozantrone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegaspargase</intervention_name>
    <description>Given IV. If participant is allergic to pegaspargase, Asparaginase Erwinia Chrysanthemi will be used.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>PEG-asparaginase</other_name>
    <other_name>Oncaspar®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asparaginase Erwinia Chrysanthemi</intervention_name>
    <description>Asparaginase Erwinia Chrysanthemi will be used in case of allergy or intolerance of participant to PEG-asparaginase. Given IV (preferred) or intramuscularly (IM).</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Erwinia chrysanthemi</other_name>
    <other_name>Erwinase®</other_name>
    <other_name>Erwinaze^T^M</other_name>
    <other_name>Crisantaspase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Given IV.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Velcade®</other_name>
    <other_name>PS-341</other_name>
    <other_name>MLN341</other_name>
    <other_name>LDP-341</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vorinostat</intervention_name>
    <description>Taken PO or NG.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Solinza®</other_name>
    <other_name>Suberoylanidide Hydroxamic Acid</other_name>
    <other_name>SAHA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Cytoxan®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mercaptopurine</intervention_name>
    <description>Given PO or NG.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>6-MP</other_name>
    <other_name>Purinethol®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given IV.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>MTX</other_name>
    <other_name>High Dose MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin Calcium</intervention_name>
    <description>Leucovorin rescue PO or IV.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Wellcovorin®</other_name>
    <other_name>Folinic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IV.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Ara-C</other_name>
    <other_name>Cytosar-U®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV. In case of participant allergy, etoposide phosphate (Etopophos®) will be given.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>VP-16</other_name>
    <other_name>Vepesid®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Given IV.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Oncovin®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is ≤ 365 days of age at the time of diagnosis.

          -  Patient has newly diagnosed acute lymphoblastic leukemia (ALL) or acute
             undifferentiated leukemia with ≥25% blasts in the bone marrow (M3), with or without
             extramedullary disease. Patients with T-cell ALL are eligible. Patients with bilineage
             or biphenotypic acute leukemia are eligible, provided the morphology and
             immunophenotype are predominantly lymphoid.

          -  Limited prior therapy, including systemic glucocorticoids for one week or less, one
             dose of vincristine, and one dose of intrathecal chemotherapy.

          -  Written informed consent following Institutional Review Board, NCI, FDA, and Office
             for Human Research Protections (OHRP) Guidelines.

        Exclusion Criteria:

          -  Patients with prior therapy, other than therapy specified in the Inclusion Criteria.

          -  Patients with mature B-cell ALL or acute myelogenous (AML).

          -  Patients with Down syndrome.

          -  Inability or unwillingness of legal guardian/representative to give written informed
             consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>365 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanja A. Gruber, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tanja A. Gruber, MD, PhD</last_name>
    <phone>866-278-5833</phone>
    <email>tanja.gruber@stjude.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>St. Jude Referral Office</last_name>
    <phone>866-278-5833</phone>
    <email>referralinfo@stjude.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Gaynon, MD</last_name>
      <phone>323-361-4110</phone>
      <email>pgaynon@chla.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Gaynon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivan Kirov, MD</last_name>
      <phone>714-997-3000</phone>
      <email>ikirov@choc.org</email>
    </contact>
    <investigator>
      <last_name>Ivan Kirov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norman J. Lacayo, MD</last_name>
      <phone>650-497-8953</phone>
      <email>lacayon@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Norman J. Lacayo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital and Health Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Schiff, MD</last_name>
      <phone>858-966-5983</phone>
      <email>dschiff@chsd.org</email>
    </contact>
    <investigator>
      <last_name>Deborah Schiff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Clinics of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Richards, MD</last_name>
      <phone>612-813-5193</phone>
      <email>Michael.richards@childrensmn.org</email>
    </contact>
    <investigator>
      <last_name>Michael Richards, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Jude Affiliate-Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Bolen, MD</last_name>
      <phone>704-384-1900</phone>
      <email>cybolen@novanthealth.org</email>
    </contact>
    <investigator>
      <last_name>Christine Bolen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Breese, MD, PhD</last_name>
      <phone>513-636-2799</phone>
      <email>erin.breese@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Erin Breese, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies &amp; Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yousif Matloub, MD</last_name>
      <phone>216-844-5437</phone>
      <email>yousif.matloub@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Yousif Matloub, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bill Chang, MD</last_name>
      <phone>503-494-1080</phone>
      <email>changb@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Bill Chang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanja A. Gruber, MD, PhD</last_name>
      <phone>866-278-5833</phone>
      <email>tanja.gruber@stjude.org</email>
    </contact>
    <contact_backup>
      <last_name>Referral Office</last_name>
      <phone>866-278-5833</phone>
      <email>referralinfo@stjude.org</email>
    </contact_backup>
    <investigator>
      <last_name>Tanja A. Gruber, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of the King's Daughters (CHKD)</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Lowe, MD</last_name>
      <phone>757-668-7243</phone>
      <email>eric.lowe@chkd.org</email>
    </contact>
    <investigator>
      <last_name>Eric Lowe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3A 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor A. Lewis, MD</last_name>
      <phone>403-220-6898</phone>
      <email>victor.lewis@ahs.ca</email>
    </contact>
    <investigator>
      <last_name>Victor A. Lewis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's &amp; Women's Health Centre of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirk R. Schultz, MD</last_name>
      <phone>604-875-2345</phone>
      <phone_ext>6477</phone_ext>
      <email>kschultz@mail.ubc.ca</email>
    </contact>
    <investigator>
      <last_name>Kirk R. Schultz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McMaster Children's Hospital at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L85 4J9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uma Athale, MD</last_name>
      <phone>905-521-2100</phone>
      <phone_ext>73376</phone_ext>
      <email>athaleu@mcmaster.ca</email>
    </contact>
    <investigator>
      <last_name>Uma Athale, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Montreal Children's Hospital (MUHC-McGill)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Vezina, MD</last_name>
      <phone>514-412-4445</phone>
      <email>catherine.vezina@muhc.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Catherine Vezina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Sainte-Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>HcT 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henrique Bittencourt, MD</last_name>
      <phone>514-345-4931</phone>
      <email>henrique.bittencourt.hsj@ssss.gouv.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Yvan Samson</last_name>
      <email>yvan.samson@umontreal.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Henrique Bittencourt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Quebec</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Michon, MD</last_name>
      <phone>418-525-4444</phone>
      <email>bruno.michon@mail.chuq.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Bruno Michon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stjude.org</url>
    <description>St. Jude Children's Research Hospital</description>
  </link>
  <link>
    <url>http://www.stjude.org/protocols</url>
    <description>Clinical Trials Open at St. Jude</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2015</study_first_submitted>
  <study_first_submitted_qc>September 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2015</study_first_posted>
  <last_update_submitted>February 14, 2018</last_update_submitted>
  <last_update_submitted_qc>February 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Vorinostat</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

